EA201691367A1 - Кристаллические формы дималеата афатиниба - Google Patents

Кристаллические формы дималеата афатиниба

Info

Publication number
EA201691367A1
EA201691367A1 EA201691367A EA201691367A EA201691367A1 EA 201691367 A1 EA201691367 A1 EA 201691367A1 EA 201691367 A EA201691367 A EA 201691367A EA 201691367 A EA201691367 A EA 201691367A EA 201691367 A1 EA201691367 A1 EA 201691367A1
Authority
EA
Eurasian Patent Office
Prior art keywords
afatinib
dimaleate
crystal shapes
shapes
crystal
Prior art date
Application number
EA201691367A
Other languages
English (en)
Other versions
EA031059B1 (ru
Inventor
Михаэла Туксар
Марина Раткай
Мирослав Зегарач
Original Assignee
Тева Фармасьютикалз Интернэшнл Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикалз Интернэшнл Гмбх filed Critical Тева Фармасьютикалз Интернэшнл Гмбх
Publication of EA201691367A1 publication Critical patent/EA201691367A1/ru
Publication of EA031059B1 publication Critical patent/EA031059B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid

Abstract

Настоящее изобретение охватывает кристаллические формы дималеата афатиниба и способы их применения.
EA201691367A 2014-01-02 2015-01-02 Кристаллическая форма альфа дималеата афатиниба EA031059B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461922982P 2014-01-02 2014-01-02
US201461932317P 2014-01-28 2014-01-28
US201462016155P 2014-06-24 2014-06-24
PCT/US2015/010013 WO2015103456A1 (en) 2014-01-02 2015-01-02 Crystalline forms of afatinib di-maleate

Publications (2)

Publication Number Publication Date
EA201691367A1 true EA201691367A1 (ru) 2016-10-31
EA031059B1 EA031059B1 (ru) 2018-11-30

Family

ID=52347491

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691367A EA031059B1 (ru) 2014-01-02 2015-01-02 Кристаллическая форма альфа дималеата афатиниба

Country Status (5)

Country Link
US (1) US9630952B2 (ru)
EP (1) EP3089976B1 (ru)
EA (1) EA031059B1 (ru)
IL (1) IL246385B (ru)
WO (1) WO2015103456A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016051380A1 (en) * 2014-10-01 2016-04-07 Sun Pharmaceutical Industries Limited Crystalline form of afatinib dimaleate
AU2016248025B2 (en) * 2015-04-17 2020-12-24 Hetero Labs Ltd Polymorphs of AFATINIB and its salts and process for the preparation of quinazolinyl derivatives
EP3337461A1 (en) * 2015-08-21 2018-06-27 Fresenius Kabi Oncology Ltd Pharmaceutical compositions comprising afatinib
WO2017093789A1 (en) * 2015-12-03 2017-06-08 Mylan Laboratories Ltd. Polymorphic forms of afatinib dimaleate
CN106866641A (zh) * 2015-12-11 2017-06-20 河北神威药业有限公司 一种阿法替尼的精制方法
CN106916147A (zh) * 2015-12-25 2017-07-04 中美华世通生物医药科技（武汉）有限公司 化合物及其制备方法和用途
CN106045983A (zh) * 2016-06-02 2016-10-26 苏州富士莱医药股份有限公司 阿法替尼的制备方法
CN105968103B (zh) * 2016-07-18 2018-11-27 山东罗欣药业集团恒欣药业有限公司 抗肿瘤药物阿法替尼的合成方法
CN106565692A (zh) * 2016-11-03 2017-04-19 常茂生物化学工程股份有限公司 一种阿法替尼合成工艺的改进方法
CN110461832A (zh) 2017-04-06 2019-11-15 庄信万丰股份有限公司 阿法替尼二马来酸盐的新形式
CN108467387A (zh) * 2018-06-22 2018-08-31 苏州市贝克生物科技有限公司 阿法替尼异构体杂质的合成方法
CN110563710B (zh) * 2019-09-21 2020-05-19 广东安诺药业股份有限公司 一种马来酸阿法替尼的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10349113A1 (de) * 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
EA024026B1 (ru) * 2010-11-25 2016-08-31 Рациофарм Гмбх Новые соли и полиморфные формы афатиниба
EP2753616A1 (en) * 2011-10-06 2014-07-16 Ratiopharm GmbH Crystalline forms of afatinib di-maleate

Also Published As

Publication number Publication date
US20160122329A1 (en) 2016-05-05
EP3089976A1 (en) 2016-11-09
EP3089976B1 (en) 2019-08-14
WO2015103456A1 (en) 2015-07-09
US9630952B2 (en) 2017-04-25
IL246385A0 (en) 2016-08-31
EA031059B1 (ru) 2018-11-30
IL246385B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
EA201691367A1 (ru) Кристаллические формы дималеата афатиниба
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
CL2016002731A1 (es) Herbicidas de piridazinona
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
MX2016016886A (es) Anticuerpos anti-axl.
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
DK2897382T3 (da) Forbedring af binaural kilde
EP3201190A4 (en) Crystalline form of afatinib dimaleate
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
EA201790428A1 (ru) Синтез энт-прогестерона и его промежуточных соединений
EA201691203A1 (ru) Твёрдые формы тенофовира
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1
ECSP17015682A (es) Inhibidores cristalinos de bace

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM